Cost-effectiveness of infective endocarditis prophylaxis for mitral valve prolapse with or without a mital regurgitant murmur.
To assess the cost-effectiveness of prevention of infective endocarditis (IE) and to calculate cost-effectiveness of currently recommended regimens in patients with mitral valve prolapse (MVP), data on risk of death, complications, and health-care use, and cumulative incremental health-care costs due to the occurrence of IE were combined with data on the prevalence and manifestations of MVP, estimated years of life lost, in efficacy of antibiotic prophylaxis.
Effectiveness and costs of standard endocarditis prophylaxis regimens were calculated per IE case prevented and years of life saved.
Mots-clés Pascal : Prolapsus, Valvule mitrale, Régurgitation, Endocardite, Bactériose, Infection, Prévention, Chimiothérapie, Antibiotique, Coût, Homme, Appareil circulatoire pathologie, Cardiopathie valvulaire, Cardiopathie, Endocarde pathologie
Mots-clés Pascal anglais : Prolapsus, Mitral valve, Regurgitation, Endocarditis, Bacteriosis, Infection, Prevention, Chemotherapy, Antibiotic, Costs, Human, Cardiovascular disease, Cardiac valvular disease, Heart disease, Endocardial disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0071816
Code Inist : 002B05B02D. Création : 09/06/1995.